|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-9-17
|
|
pubmed:abstractText |
The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
113-20
|
|
pubmed:meshHeading |
pubmed-meshheading:19404641-Aged,
pubmed-meshheading:19404641-Ampulla of Vater,
pubmed-meshheading:19404641-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19404641-Bile Duct Neoplasms,
pubmed-meshheading:19404641-Bile Ducts, Intrahepatic,
pubmed-meshheading:19404641-Biliary Tract Neoplasms,
pubmed-meshheading:19404641-Cholangiocarcinoma,
pubmed-meshheading:19404641-Common Bile Duct Neoplasms,
pubmed-meshheading:19404641-Disease-Free Survival,
pubmed-meshheading:19404641-Doxorubicin,
pubmed-meshheading:19404641-Female,
pubmed-meshheading:19404641-Gallbladder Neoplasms,
pubmed-meshheading:19404641-Humans,
pubmed-meshheading:19404641-L-Lactate Dehydrogenase,
pubmed-meshheading:19404641-Male,
pubmed-meshheading:19404641-Middle Aged,
pubmed-meshheading:19404641-Multivariate Analysis,
pubmed-meshheading:19404641-Neoplasm Staging,
pubmed-meshheading:19404641-Prognosis,
pubmed-meshheading:19404641-Survival Rate,
pubmed-meshheading:19404641-Tegafur,
pubmed-meshheading:19404641-Treatment Outcome,
pubmed-meshheading:19404641-Uracil
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
|
|
pubmed:affiliation |
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. jfuruse@ks.kyorin-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
